Prodrugs of glutamine analogs
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61388963%3A_____%2F19%3A00519635" target="_blank" >RIV/61388963:_____/19:00519635 - isvavai.cz</a>
Result on the web
<a href="https://worldwide.espacenet.com/publicationDetails/originalDocument?FT=D&date=20190702&DB=&locale=en_EP&CC=US&NR=10336778B2&KC=B2&ND=4#" target="_blank" >https://worldwide.espacenet.com/publicationDetails/originalDocument?FT=D&date=20190702&DB=&locale=en_EP&CC=US&NR=10336778B2&KC=B2&ND=4#</a>
DOI - Digital Object Identifier
—
Alternative languages
Result language
angličtina
Original language name
Prodrugs of glutamine analogs
Original language description
The disclosure provides compounds having formula (I) and the pharmaceutically acceptable salts thereof, wherein R1, R2, R2′, and X are as defined as set forth in the specification. Compounds having formula (I) are prodrugs that release glutamine analogs, e.g., 6-diazo-5-oxo-L-norleucine (DON). The disclosure also provides compounds having formula (I) for use in treating cancer.
Czech name
—
Czech description
—
Classification
Type
P - Patent
CEP classification
—
OECD FORD branch
10401 - Organic chemistry
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2019
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Patent/design ID
US10336778
Publisher
US001 -
Publisher name
United States Patent and Trademark Office (USPTO)
Place of publication
Alexandria
Publication country
US - UNITED STATES
Date of acceptance
Jul 2, 2019
Owner name
The Johns Hopkins University - Ústav organické chemie a biochemie AV ČR, v. v. i
Method of use
B - Výsledek je využíván orgány státní nebo veřejné správy
Usage type
A - K využití výsledku jiným subjektem je vždy nutné nabytí licence